Blog

Healthcare Wants to Own Its Agentic Future

The build-vs-buy debate in healthcare AI is over. Deloitte found 61% of healthcare leaders are already building their own agents, and Lilly, Novo, Stanford, and Humana are proving why: an agent trained on your data is your moat; a rented one is a subscription. What operational long-tail workflows are you focused on building yourself?

By Frank Wang

4 min read·August 3, 2026

The build-vs-buy debate in healthcare AI is over. Payers, providers, and life sciences companies are building their own AI agents on their own data. The open question is whether they can govern what they build.

BY THE NUMBERS

The Evidence Is in the Survey Data

Deloitte's Center for Health Solutions surveyed 100 US health system and health plan technology executives. The results settle the question.

61%
Already building agentic AI initiatives or have secured budgets for them
85%
Plan to increase agentic AI investment over the next 2–3 years
98%
Expect at least 10% cost savings within 2–3 years; more than a third project savings above 20%
70%
Of health plans prioritize agentic AI for utilization management, prior auth, and claims

Two years ago, fewer than half of these leaders believed AI would deliver near-term value at all. The shift happened fast, and it happened in one direction. Toward ownership.

The Evidence Is in the Behavior

Watch what organizations do, not what they say.

Providers Are Building

Stanford Health Care is piloting agents that mine the EHR and surface evidence for treatment decisions. Sentara Health automated nursing documentation and recovered thousands of nursing hours within months. These are core clinical workflows, run on the organization's own data, under its own roof.

Payers Are Building

Humana deployed agents that summarize member calls and anticipate needs so staff resolve inquiries faster. The workflows going agentic first sit closest to the plan's competitive core.

Life Sciences Went Furthest

Eli Lilly deployed the largest AI factory wholly owned and operated by a pharmaceutical company, with over 1,000 GPUs powering scientific agents across discovery, manufacturing, and commercial. Novo Nordisk spent a year building trial-compression agents trained on its own internal data. The two most valuable pharma companies on earth chose ownership.

WHY OWNERSHIP WINS
The moat rule: Every competitor can buy the same point solution. An agent trained on your denial patterns, your member population, and your protocols is a moat. A rented one is a subscription.

The math makes ownership more than a preference. Healthcare spends roughly $83B a year in staff time on nine tracked administrative transactions, and prior auth is only one of the nine. Total excess administrative spend runs near $528B annually. So the tracked transactions cover perhaps 15–20% of the labor.

The rest is the operational long tail. Appeals and grievances. Credentialing. Contract loading. Benefit configuration. Chart abstraction. Quality reporting. Each of these workflows at a single organization is a $200K–$2M per year labor problem. Each is shaped by bespoke policies, state regulations, and legacy system quirks that few other organizations share.

That specificity is why no vendor will ever solve the long tail. A venture-backed point solution needs thousands of identical customers. These workflows have dozens.

The long tail is mathematically unservable by point solutions. Vendor speed was never the problem. The only way to automate it is to build it yourself.

The Gap Between Intent and Ability

Here is the tension that defines the next three years. Deloitte found the old blockers collapsing. 40% of leaders say technical talent is no longer a major barrier. Yet the same research shows many organizations lack the internal experience to build and validate AI on their own.

They are building anyway.

Building an agent takes a weekend now. Hiring it, managing it, evaluating it, and auditing it like a member of your workforce takes infrastructure most organizations don't have. Deloitte calls the result an emerging AI divide. Builders compound gains. Watchers fall behind.

Ownership Requires an Operating System

This is the problem actAVA exists to solve. Three pillars close a governed production loop.

  • actAVA KORA is a model-independent harness for building agents and managing their ROI.
  • actAVA CHRYSO is a governance suite that keeps AI transformation safe.
  • actAVA χ-BENCH is a simulation and benchmarking suite that proves agents are correctly trained.

Beneath the pillars sits actAVA CURA, a healthcare-native model the pillars feed. Together they turn production evidence into specialized, owned intelligence. Every long-tail agent you build becomes a reusable blueprint.

The results show up in production. One actAVA customer rebuilt an enrollment workflow on the platform and cut per-transaction costs roughly 11x while moving 7x faster.

The market has decided to own its agentic future. The organizations that win will be the ones with the infrastructure to own it responsibly.

Own the workforce, not the lease. Talk to actAVA.

Sources: Deloitte Center for Health Solutions agentic AI survey (2026); Deloitte 2026 US Health Care Outlook; NVIDIA/Lilly announcements (Oct 2025, Jan 2026); PYMNTS reporting on Novo Nordisk (Apr 2026); actAVA internal case study (2026).


Frank Wang

Written by

Frank Wang

CTO & Co-Founder

Share this